DWP14012 40mg

DRUG3 trials

Sponsors

Daewoong Pharmaceutical Co. LTD.

Conditions

Erosive EsophagitisHelicobacter Pylori Infected PatientsHelicobacter Pylori Infected SubjectsHelicobacter Pylori InfectionNon-Erosive Esophageal Reflux DiseaseNon-Erosive Gastro-Esophageal Reflux DiseaseNon-erosive Reflux Disease

Phase 3

Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 3)

CompletedNCT03736369

Daewoong Pharmaceutical Co. LTD.Erosive Esophagitis

Start: 2018-12-13End: 2019-08-07Updated: 2020-09-03

Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non-Erosive Gastroesophageal Reflux Disease (NERD)

Daewoong Pharmaceutical Co. LTD.Non-Erosive Esophageal Reflux Disease, Non-Erosive Gastro-Esophageal Reflux Disease, Non-erosive Reflux Disease

Start: 2023-08-31End: 2025-03-31Target: 324Updated: 2023-11-08

Study to Evaluate the Efficacy and Safety of DWP14012-based Triple Therapy in Eradication of Helicobacter Pylori

CompletedNCT06751121

Daewoong Pharmaceutical Co. LTD.Helicobacter Pylori Infected Patients, Helicobacter Pylori Infected Subjects, Helicobacter Pylori Infection

Start: 2024-02-06End: 2025-04-24Updated: 2025-12-08